Second Brazilian Consensus on the Treatment of Advanced Prostate Cancer - a SBOC-SBU-SBRT Panel Review

Prostate cancer is the second most common cancer and the fi fth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers. The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The fi rst Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of different technologies is a big challenge, especially in the Sistema Único de Saúde (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clinical Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.

Citing Articles

Investigation of radiomics models for predicting biochemical recurrence of advanced prostate cancer on pretreatment MR ADC maps based on automatic image segmentation.

Wang H, Wang K, Ma S, Gao G, Wang X J Appl Clin Med Phys. 2023; 25(4):e14244.

PMID: 38146796 PMC: 11005965. DOI: 10.1002/acm2.14244.

Treatment of complex urethral stenosis in public centers from developing countries in 21st century.

Klett D, Alom M, Wymer K, Potretzke A Int Braz J Urol. 2021; 48(2):367-368.

PMID: 34156190 PMC: 8932019. DOI: 10.1590/S1677-5538.IBJU.2021.0499.

Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective.

Dal Col L, Andrade D, Gon L, Capibaribe D, Amaro M, Truzzi N Int Braz J Urol. 2021; 48(1):175-179.

PMID: 34115454 PMC: 8691248. DOI: 10.1590/S1677-5538.IBJU.2021.0258.

Editorial Comment: Acute prostatitis after prostate biopsy under ciprofloxacin prophylaxis with or without ornidazole and pre-biopsy enema: analysis of 3.479 prostate biopsy cases.

Diniz A Int Braz J Urol. 2019; 46(1):67-69.

PMID: 31851460 PMC: 6968898. DOI: 10.1590/S1677-5538.IBJU.2019.0257.1.

The multiparametric prostate resonance imaging with the prostate imaging-reporting and data system (PI-RADS): the state of art of prostate cancer diagnosis.

Favorito L Int Braz J Urol. 2019; 45(3):422-423.

PMID: 31149788 PMC: 6786123. DOI: 10.1590/S1677-5538.IBJU.2019.03.01.

References

Berthold D, Pond G, Soban F, de Wit R, Eisenberger M, Tannock I . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2):242-5. DOI: 10.1200/JCO.2007.12.4008. View

. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355(9214):1491-8. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

Ryan C, Smith M, Fizazi K, Saad F, Mulders P, Sternberg C . Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3.... Lancet Oncol. 2015; 16(2):152-60. DOI: 10.1016/S1470-2045(14)71205-7. View

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

Sasse A, Wiermann E, Herchenhorn D, Bastos D, Schutz F, Maluf F . First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice. Int Braz J Urol. 2017; 43(3):407-415. PMC: 5462130. DOI: 10.1590/S1677-5538.IBJU.2016.0490. View

Fitzmaurice C, Akinyemiju T, Al Lami F, Alam T, Alizadeh-Navaei R, Allen C . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018; 4(11):1553-1568. PMC: 6248091. DOI: 10.1001/jamaoncol.2018.2706. View

Sun M, Choueiri T, Hamnvik O, Preston M, de Velasco G, Jiang W . Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016; 2(4):500-7. DOI: 10.1001/jamaoncol.2015.4917. View

10.

Kolinsky M, de Bono J . The Ongoing Challenges of Targeting the Androgen Receptor. Eur Urol. 2015; 69(5):841-3. DOI: 10.1016/j.eururo.2015.10.052. View

11.

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4):232-40. DOI: 10.3322/canjclin.22.4.232. View

12.

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

13.

Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Stopeck A . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011; 23(5):1341-1347. DOI: 10.1093/annonc/mdr435. View

14.

Metcalfe M, Smaldone M, Lin D, Aparicio A, Chapin B . Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017; 35(4):125-134. DOI: 10.1016/j.urolonc.2017.01.001. View

15.

James N, de Bono J, Spears M, Clarke N, Mason M, Dearnaley D . Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017; 377(4):338-351. PMC: 5533216. DOI: 10.1056/NEJMoa1702900. View

16.

Chi B, Chang I, Lee D, Park S, Kim K, Moon Y . Low-Dose Unenhanced Computed Tomography with Iterative Reconstruction for Diagnosis of Ureter Stones. Yonsei Med J. 2018; 59(3):389-396. PMC: 5889991. DOI: 10.3349/ymj.2018.59.3.389. View

17.

Schmid S, Omlin A, Blum D, Strasser F, Gillessen S, Rothermundt C . Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review. Ann Oncol. 2015; 26(11):2221-47. DOI: 10.1093/annonc/mdv326. View

18.

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

19.

Nishiyama T . Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature. Urol Oncol. 2013; 32(1):38.e17-28. DOI: 10.1016/j.urolonc.2013.03.007. View

20.

Hussain M, Tangen C, Berry D, Higano C, Crawford E, Liu G . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013; 368(14):1314-25. PMC: 3682658. DOI: 10.1056/NEJMoa1212299. View